2
Views
3
CrossRef citations to date
0
Altmetric
HYPERLIPIDEMIA THERAPY

Hyperlipidemia therapy

Can it prevent coronary atherosclerosis?

Pages 207-211 | Published online: 07 Jul 2016

References

  • Small DM. Cellular mechanisms for lipid deposition in atherosclerosis. N Engl J Med 1977: 297: 873–7
  • Nicolosi RJ. Hajnacki JL. Llansa N, et al. Diet and llpoprotein influence on primate atherosclerosis (39863). Proc Soc Exp Biol Mrd 1977: 156(1): 1–7
  • Nash DT. Dr Nash's natural diet book. New York: Grosset fit Dunlap. 1978
  • Nash DT, Gensini G, Simon H. et al. The Erysichthon syndrome: progression of coronary atherosclerosis and hyperlipidemia Circulation 1977;56(3): 363–5
  • Kuo PT, Hayase K. Kostis JB. et al. Use of combined diet and colestipol in long-term (7–71b years) treatment of patients with type II hyperilpoproteinemia. Circulation 1979: 59(2): 199–211
  • Barndt R Jr. Blankenhorn DH, Crawford DW. et al. Regression and progression of early femoral atherosclerosis in treated hyprelipoproteinemic patients. Ann Intern Med 1977: 86: 139–46
  • Nash DT. Gensini G. Esente P. Lipid lowering therapy and the progression of coronary artery disease Circulation 1980;62(Suppl III): 122
  • Nash DT. Probucol. a new cholesterol lowering drug. J Med 1975: 6: 305–15
  • Nash DT. Safety and efficacy of probucol during one year of administration. J Clin Pharmacol 1974: 14: 470–5
  • Davignon J, LeLorier J. Experience with probucol in the treatment of hypercholesterolemia. Presented before the VII International Symposium on Drugs Affecting Lipid Metabolism. Milan. Italy. 1980
  • Harris RS. Long term oral administration of 4.4′ (lsopropylidenedtthio) bis(2.6 dl-t-butylphenol)in the management of hypercholesierolemia. J Am Geriatr Soc 1974: 22: 167–70
  • Heel RC. Brogden RN. Speight TM. et al. Probucol: a review of its pharmacological properties and therapeutic use in patients with hypereholesterolemia. Drugs 1978: 15: 409–28
  • Wissler RW. Vesselinovitch D. The effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkeys. Presented before Symposium on Lipoproteins and Athcrosdcrosis. Lugano. Switzerland. 1981: 1–3
  • McCaughan D. The long term effects of probucol on serum lipid levels. Arch Intern Med 1981: 141: 1428–32
  • Nash DT. Gemfibrozil—a new lipid lowering agent J Med 1980: 11: 107–16

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.